IGHE and asthma: Of interest, Corren et al. assessed dupilumab's effect in QUEST patients with (n = 1,083) and without (n = 819) atopic asthma (total serum IgE ≥30 IU/ml and ≥1 perennial aeroallergen-specific IgE ≥0.35 kU/L at baseline), demonstrating its ability to reduce severe exacerbation rates, improve FEV1 and asthma control, and suppress type 2 biomarkers of inflammation in both the subgroups.